Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H-[1]benzothieno[2,3-b][1,5] benzodiazepine maleate)

Neuropsychopharmacology

Volumn 26, Issue 4, 2002, Pages 456-467

  Morimoto, Toshihiko ^a   Hashimoto, Kenji ^a   Yasumatsu, Hiroshi ^a   Tanaka, Hiroshi ^a   Fujimura, Masatake ^a   Kuriyama, Makoto ^a   Kimura, Koreichi ^a   Takehara, Shuzo ^a   Yamagami, Keiji ^a  

^a Welfide Corporation   (Japan)

Author keywords

Atypical antipsychotic drugs; Dizocilpine ((+) MK 801); Dopamine; Glutamate; Schizophrenia; Y 931

Indexed keywords

8 FLUORO 12 (4 METHYLPIPERAZIN 1 YL) 6H [1]BENZOTHIENO[2,3 B][1,5]BENZODIAZEPINE MALEATE; ALPHA ADRENERGIC RECEPTOR; APOMORPHINE; CLOZAPINE; DIZOCILPINE; DOPAMINE RECEPTOR; HALOPERIDOL; HISTAMINE RECEPTOR; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; RISPERIDONE; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; Y 931;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; BINDING ASSAY; BRAIN REGION; CATALEPSY; CELL VACUOLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HYPERACTIVITY; LOCOMOTION; MALE; NEGATIVE SYNDROME; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SOCIAL ISOLATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; AVOIDANCE LEARNING; BENZODIAZEPINES; CATALEPSY; DIZOCILPINE MALEATE; DOPAMINE AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; MALE; MOTOR ACTIVITY; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NEUROTRANSMITTER; SOCIAL BEHAVIOR;

EID: 0036196819     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00368-2     Document Type: Article

References (52)

1. Serotonin model of schizophrenia: Emerging role of glutamate mechanisms
2. Phencyclidine-induced psychosis
3. Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade
4. Pharmacological actions of the atypical antipsychotic drug clozapine: A review
5. 3H-SCH23390, a selective D-1 receptor antagonist ligand, in rat striatum
6. Recent advances in the pharmacotherapy of schizophrenia
7. Clozapine: Efficacy and safety
8. Positive and negative symptom response to clozapine in schizophrenic patients with and without deficit syndrome
9. Beta adrenergic receptor binding in membrane preparations from mammalian brain
10. In vitro and in vivo biochemistry of olanzapine: A novel, atypical antipsychotic drugs
11. Interaction between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease
12. The glutamatergic dysfunction hypothesis for schizophrenia
13. 3H-Spiroperidol labels dopamine receptors in pituitary and brain
14. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity
15. Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine
16. 3H-prazosin to rat brain β-adrenergic receptors
17. Phasis versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia
18. Adverse effects of clozapine
19. 3H] 8-Hydroxy-2-(di-n-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of rat brain
20. Dizocilpine-induced neuropathological changes in rat retrosplenial cortex are reversed by subsequent clozapine treatment
21. Rolipram, a selective phosphodiesterase type-IV inhibitor, prevents induction of heat shock protein HSP-70 and hsp-70 mRNA in rat retrosplenial cortex by the NMDA receptor antagonist dizocilpine
22. Recent advances in the phencyclidine model of schizophrenia
23. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
24. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
25. Treatment of schizophrenia
26. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans
27. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in human
28. Serotonin-dopamine interaction and its relevance to schizophrenia
29. Study of a new schizophrenomimetic drug - Sernyl
30. 2 receptor binding sites
31. The retrosplenial cortex and emotion: New insights from functional neuroimaging of the human brain
32. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine
33. The role of serotonin in schizophrenia and the mechanism of action of antipsychotic drugs
34. Cognition, schizophrenia, and the atypical antipsychotic drugs
35. Review and management of clozapine side effects
36. Glutamate receptor dysfunction and schizophrenia
37. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs
38. NMDA antagonist neurotoxicity: Mechanism and prevention
39. NMDA receptor hypofunction model of schizophrenia
40. The binding of serotonergic ligands to the porcine choroid plexus: Characterization of a new type of serotonin recognition site
41. Clinical and biogenic response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine
42. Atypical antipsychotics: Are some more atypical than others?
43. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
44. Posterior cingulate cortex and spatial memory: A microlimnology analysis
45. Schizophrenia and glutamatergic transmission
46. 3H]mepyramine
47. Multiple apparent alpha-noradrenergic receptor binding sites in rat brain: Effect of 6-hydroxydopamine
48. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons
49. 3H]quinuclidinyl benzilate
50. The pharmacological properties of Y-23684, a benzodizapine receptor partial agonist
51. 3H]MK-801 in brain synaptic membranes treated with Triton X-100